Who is sponsoring NCT03273855?

NCT03273855 is sponsored by University Hospital of North Norway.

What drugs are being tested in NCT03273855?

Interventions in NCT03273855: Fecal microbiota transplantation, Placebo: fecal microbiota transplantation.

What condition does NCT03273855 study?

NCT03273855 studies Obesity, Morbid.

Is NCT03273855 still recruiting?

NCT03273855 is currently status unknown. Last updated 20 January 2023.

Last reviewed 2023-01-20 · How we verify

NCT03273855: RCTFMTOb

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Controlled Trial of Fecal Microbiota Transplantation in Severe Obesity

Status unknown NA Last updated 20 January 2023

What this trial tests

NA trial testing Fecal microbiota transplantation in Obesity, Morbid in 60 participants. Status unknown.

Timeline

13 May 2019

Primary endpoint
1 May 2023

1 May 2023

Quick facts

Lead sponsor	University Hospital of North Norway
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	13 May 2019
Primary completion	1 May 2023
Estimated completion	1 May 2023
Sites	1 location across Norway

Drugs / interventions tested

Fecal microbiota transplantation — full drug profile →
Placebo: fecal microbiota transplantation

Conditions studied

Obesity, Morbid — all drugs for Obesity, Morbid →

Sponsor

University Hospital of North Norway

Who can join

Adults 18 to 69, any sex, with Obesity, Morbid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double-blinded and placebo controlled prospective trial with sixty patients to investigate the effect of fecal microbiota transplantation (FMT) on body weight in patients with severe obesity. We will also collect data that possibly could give a better understanding of mechanisms of this correlation.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Fecal microbiota transplantation beyond Clostridioides difficile infections.
Wortelboer K, Nieuwdorp M, Herrema H. · · 2019 · cited 111× · PMID 31201141 · DOI 10.1016/j.ebiom.2019.05.066
Unraveling the gut microbiota's role in obesity: key metabolites, microbial species, and therapeutic insights.
Iqbal M, Yu Q, Tang J, Xiang J. · · 2025 · cited 15× · PMID 40183584 · DOI 10.1128/jb.00479-24
Over-feeding the gut microbiome: A scoping review on health implications and therapeutic perspectives.
Barone M, D'Amico F, Fabbrini M, Rampelli S, et al · · 2021 · cited 12× · PMID 34887627 · DOI 10.3748/wjg.v27.i41.7041
Randomised, placebo-controlled, double-blinded trial of fecal microbiota transplantation in severe obesity: a study protocol.
Hanssen HM, Hanssen HM, Fjellstad MS, Skjevling L, et al · · 2023 · cited 2× · PMID 38151280 · DOI 10.1136/bmjopen-2023-073242

Verify or expand the search:

Other trials of Fecal microbiota transplantation

Trials testing the same drug.

NCT07149441 — Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study · NA · active not recruiting
NCT06478602 — Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis · Phase 3 · completed
NCT06290258 — Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder. · Phase 1, PHASE2 · recruiting
NCT05873348 — A Controlled Study on Regulation of Systemic Inflammation by Fecal Bacteria Transplantation in Patients With COVID-19. · NA · completed
NCT06268990 — FMT in Obesity: RYGB vs. LEAN vs. Autologous FMT · NA · recruiting

Other recruiting trials for Obesity, Morbid

Currently open trials in the same condition.

NCT07119437 — Low Impact Laparoscopy In Bariatric Surgery · NA · recruiting
NCT05927519 — Comparison of Airtraq in Class 2-3 Obese and Nonobese Men During Intubation: a Prospective Randomized Clinical Study · NA · recruiting
NCT06530212 — Sleeve Gastrectomy With Jejuno-ileal Bypass Versus Single Anastomosis Sleeve Jejunal Bypass · NA · recruiting
NCT06477120 — Time-restricted Eating Among Pregnant Females With Severe Obesity · NA · recruiting
NCT06119516 — Transpulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study. · NA · recruiting

Other University Hospital of North Norway trials

Trials by the same sponsor.

NCT07343895 — Population-based Atrial Fibrillation Screening in Individuals With NT-proBNP Above Median in the Tromsø Study · NA · recruiting
NCT07149246 — The Effect of a 6-month Dietitian-tailored Nutrition Intervention to Patients With Critical Illness (DETAIL) · NA · recruiting
NCT07092904 — Myocardial Infarction Safe Emergency Medicine Accompanying Study: Providing Reperfusion Therapy Within the Recommended T · not yet recruiting
NCT07530588 — Decentralized Imaging by REmote Computer Tomography for Cerebral Infarct Thrombolysis · NA · recruiting
NCT06881758 — High Intensity Training for Patients with Anxiety · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03273855 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital of North Norway
Last refreshed: 20 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03273855.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing